Streetbeat News

Price Targets

SIRI

Benchmark analyst Matthew Harrigan maintains a Buy rating on Sirius XM Holdings but lowers the price target from $65 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:08 pm

EVH

Evolent Health (NYSE:EVH) has received mixed analyst ratings, with a recent positive shift in average price targets. Analysts have provided a range of price targets from $31.00 to $45.00, with an average of $38.29, up 4.3% from the previous average. The company has shown strong revenue growth and financial health metrics, despite a negative net margin.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 3:00 pm

B

Barnes Group Inc (NYSE:B) has received mixed analyst ratings over the past three months, with a recent average price target of $46.25, reflecting a 7.56% increase from the previous target. Analysts have adjusted their ratings and price targets in response to market conditions, with some raising and others lowering their expectations. Despite positive revenue growth, Barnes Gr faces challenges with profitability, return on equity, and debt management.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 3:00 pm

VRTX

Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals, maintaining a price target of $480.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:57 pm

SAVA

Cassava Sciences Inc. (NASDAQ:SAVA) has settled SEC charges for $40 million over misleading statements related to its Alzheimer's drug trial. The settlement allows the company to focus on its drug development. HC Wainwright upgraded the stock to Buy with a $116 price target, anticipating positive trial results.

Portfolio Pulse from Vandana Singh

October 08, 2024 | 2:57 pm

SPRY

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintained a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:50 pm

LCID

Cantor Fitzgerald analyst Andres Sheppard has reiterated a Neutral rating on Lucid Group (NASDAQ:LCID) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:48 pm

LYV

Macquarie analyst Paul Golding maintains an Outperform rating on Live Nation Entertainment and raises the price target from $125 to $130.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:46 pm

NVDA

UBS analyst Timothy Arcuri has reiterated a Buy rating on NVIDIA (NASDAQ:NVDA) and maintained a price target of $150.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:45 pm

KRON

Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Kronos Bio (NASDAQ:KRON) and maintained a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 2:37 pm